Weekly Epirubicin for Breast Cancer with Liver Metastases
Author Information
Author(s): C.J. Twelves, S.M. O'Reilly, R.E. Coleman, M.A. Richards, R.D. Rubens
Primary Institution: Imperial Cancer Research Fund Clinical Oncology Unit, Guy's Hospital
Hypothesis
Can weekly epirubicin treatment be effective for breast cancer patients with liver metastases and abnormal liver biochemistry?
Conclusion
Epirubicin is effective in treating breast cancer patients with liver metastases, even when liver biochemistry is initially abnormal.
Supporting Evidence
- 30% of patients showed an objective response to treatment according to UICC criteria.
- Median response duration was 27 weeks.
- Seven patients had improved liver biochemistry despite stable disease.
- Treatment was well tolerated with manageable side effects.
Takeaway
Doctors gave a medicine called epirubicin to 36 women with breast cancer that had spread to their liver, and it helped some of them feel better.
Methodology
Patients received 25 mg/m² of epirubicin intravenously every week, with dose adjustments based on myelosuppression.
Potential Biases
Potential bias due to lack of randomization and exclusion of patients with previous anthracycline treatment.
Limitations
The study had a small sample size and a short follow-up period.
Participant Demographics
All participants were women with histologically proven breast cancer and liver metastases.
Statistical Information
P-Value
0.025
Confidence Interval
15-45%
Statistical Significance
p=0.025
Want to read the original?
Access the complete publication on the publisher's website